An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called CoreAgeRx is rolling out new preventive “longevity” treatment plans that include tiny, regular doses of semaglutide and tirzepatide, plus sermorelin therapy. The announcement was reported by a local TV outlet. The way it was phrased suggests these are being offered as preventive or anti-aging services rather than treatments for diagnosed disease. Semaglutide and tirzepatide are drugs people have heard about because they are used to treat diabetes and, at higher doses, help with weight loss. In plain terms: semaglutide acts like a natural gut hormone that tells your brain you’re full and slows stomach emptying. Tirzepatide works on two related hormone systems that control blood sugar and appetite. Sermorelin is different — it’s a short-acting compound that nudges the body to produce more of its own growth hormone-releasing factor, which some clinics use believing it may affect muscle, fat, or energy levels. The announcement didn’t present new clinical trial data. It’s a service launch: the company plans to offer “microdosing” regimens of these drugs and sermorelin as part of preventive longevity packages. That means smaller-than-standard doses given over time, purportedly to get benefits with fewer side effects. The report didn’t say whether these specific microdosing schedules have been tested in rigorous studies for longevity, nor did it provide numbers about effectiveness. So we don’t have evidence here that these regimens actually extend life or prevent age-related diseases — only that the company is offering them. Why might people care? Lots of adults are interested in anything that promises better energy, slimmer waistlines, clearer blood markers, or slower aging. For someone already struggling with weight or metabolic problems, semaglutide and tirzepatide can have meaningful effects when used as approved. Clinics marketing “longevity” packages tap into that interest. If microdosing truly reduces side effects while preserving benefit, that could be appealing — but that’s the question that needs solid studies. There are important caveats. Semaglutide and tirzepatide are prescription drugs with known side effects like nausea, diarrhea, and, in rare cases, more serious issues. Sermorelin and other growth-hormone–related approaches carry their own risks and uncertain long-term effects. “Preventive” or off-label uses are not always backed by the same level of evidence required for FDA approval. People with certain medical conditions, or who are pregnant or breastfeeding, should avoid these drugs unless guided by a doctor. Always ask for published evidence, ask how outcomes and safety are tracked, and consult your own physician before starting such a program. Bottom line: CoreAgeRx is offering microdosed semaglutide, tirzepatide, and sermorelin as preventive longevity services, but the announcement doesn’t provide the hard clinical proof that these regimens extend life or are safer long-term.
Source: WBOC TV